Benchmark of site- and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Glycoconjugate Journal

• Publication date

  2021-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10719-021-09994-8PMID 33835347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombospondin-1 as a Potential Therapeutic Target: Multiple Roles in Cancers.

  2020cited by this paper
• Insulin-like growth factor 2 binding protein 3 expression on endoscopic ultrasound guided fine needle aspiration specimens in pancreatic ductal adenocarcinoma

  2020cited by this paper
• A quantitative N-glycoproteomics study of cell-surface N-glycoprotein markers of MCF-7/ADR cancer stem cells

  2020cited by this paper
• Quantitative N-glycoproteomics using stable isotopic diethyl labeling.

  2020cited by this paper
• Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis

  2020cited by this paper
• Quantitative site- and structure-specific N-glycoproteomics characterization of differential N-glycosylation in MCF-7/ADR cancer stem cells

  2020cited by this paper
• 86/90Y-labeled monoclonal antibody targeting tissue factor for pancreatic cancer theranostics.

  2020cited by this paper
• Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers

  2020cited by this paper
• Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing

  2020cited by this paper
• Negative Control of Cell Migration by Rac1b in Highly Metastatic Pancreatic Cancer Cells Is Mediated by Sequential Induction of Nonactivated Smad3 and Biglycan

  2019influential reference
• Site‐ and Structure‐Specific Quantitative N‐Glycoproteomics Using RPLC‐pentaHILIC Separation and the Intact N‐Glycopeptide Search Engine GPSeeker

  2019cited by this paper
• GPSeeker Enables Quantitative Structural N-glycoproteomics for site- and structure-specific characterization of differentially expressed N-glycosylation in hepatocellular carcinoma.

  2019influential reference
• The lysosomal aminopeptidase tripeptidyl peptidase 1 displays increased activity in malignant pancreatic cysts

  2019cited by this paper
• Electron-Transfer/Higher-Energy Collision Dissociation (Ethcd)

  2019cited by this paper
• Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis.

  2019cited by this paper
• Site- and structure-specific characterization of N-glycoprotein markers of MCF-7 cancer stem cells using isotopic-labelling quantitative N-glycoproteomics.

  2019cited by this paper
• Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue

  2019cited by this paper
• Site-specific characterization and quantitation of N-glycopeptides in PKM2 knockout breast cancer cells using DiLeu isobaric tags enabled by electron-transfer/higher-energy collision dissociation (EThcD).

  2018cited by this paper
• DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells

  2018cited by this paper
• Role and mechanism of Dvl3 in the esophageal squamous cell carcinoma.

  2018cited by this paper
• Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics

  2018cited by this paper
• The heat shock protein 47 as a potential biomarker and a therapeutic agent in cancer research

  2018cited by this paper
• Lung Cancer Classification Models Using Discriminant Information of Mutated Genes in Protein Amino Acids Sequences

  2018cited by this paper
• ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling

  2018cited by this paper
• Integrating expression‐related SNPs into genome‐wide gene‐ and pathway‐based analyses identified novel lung cancer susceptibility genes

  2018cited by this paper
• Gamma‐Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt‐Beta‐Catenin Pathways in CD44+ Gastric Cancer Stem Cells

  2017cited by this paper
• Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology

  2017cited by this paper
• Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis

  2017cited by this paper
• Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

  2017cited by this paper
• Biglycan stimulates VEGF expression in endothelial cells by activating the TLR signaling pathway

  2016cited by this paper
• Efficient Procedure for N-Glycan Analyses and Detection of Endo H-Like Activity in Human Tumor Specimens.

  2016cited by this paper
• Glycoproteins and glycoproteomics in pancreatic cancer

  2016cited by this paper
• Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer

  2015cited by this paper
• Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas.

  2015cited by this paper
• The impact of carbon-13 and deuterium on relative quantification of proteins using stable isotope diethyl labeling.

  2015cited by this paper
• Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression

  2015cited by this paper
• Chaperone Hsp47 Drives Malignant Growth and Invasion by Modulating an ECM Gene Network.

  2015cited by this paper
• Mass spectrometry-based N-linked glycomic profiling as a means for tracking pancreatic cancer metastasis.

  2015cited by this paper
• Quantitative Glycoproteomics Analysis Reveals Changes in N-Glycosylation Level Associated with Pancreatic Ductal Adenocarcinoma

  2014cited by this paper
• Expression and significance of biglycan in endometrial cancer

  2014cited by this paper
• Glycoprotein Biomarker Panel for Pancreatic Cancer Discovered by Quantitative Proteomics Analysis

  2014cited by this paper
• Developments in the Identification of Glycan Biomarkers for the Detection of Cancer

  2013cited by this paper
• Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma

  2013cited by this paper
• Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a single center of internal medicine

  2013cited by this paper
• The Expression of Multiple Proteins as Prognostic Factors in Colorectal Cancer: Cathepsin D, p53, COX-2, Epidermal Growth Factor Receptor, C-erbB-2, and Ki-67

  2013cited by this paper
• Inhibitory Role of the Small Leucine-Rich Proteoglycan Biglycan in Bladder Cancer

  2013cited by this paper
• Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma

  2013cited by this paper
• Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays

  2012cited by this paper
• Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells

  2012cited by this paper
• Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers

  2012cited by this paper
• The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

  2012cited by this paper
• The relationship between tissue factor and cancer progression: insights from bench and bedside.

  2012cited by this paper
• Biglycan

  2012cited by this paper
• Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.

  2012cited by this paper
• Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer

  2011cited by this paper
• NAV3 copy number changes and target genes in basal and squamous cell cancers

  2011cited by this paper
• AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D.

  2011cited by this paper
• Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling.

  2010cited by this paper
• Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma

  2010cited by this paper
• Mass Spectrometry Based Glycoproteomics—From a Proteomics Perspective*

  2010cited by this paper
• Glycosylation of liver acute‐phase proteins in pancreatic cancer and chronic pancreatitis

  2010cited by this paper
• Pancreas-specific protein disulfide isomerase has a cell type-specific expression in various mouse tissues and is absent in human pancreatic adenocarcinoma cells: implications for its functions

  2009cited by this paper
• Adenosine-diphosphate-induced platelet adhesiveness in patients with ischaemic heart disease.

  2009cited by this paper
• Human pancreas-specific protein disulfide isomerase homolog (PDIp) is redox-regulated through formation of an inter-subunit disulfide bond.

  2009cited by this paper
• Expression of thrombospondin-1 in human pancreatic adenocarcinomas: Role in matrix metalloproteinase-9 production

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer.

  2009cited by this paper
• Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.

  2009cited by this paper
• Human pancreas-specific protein disulfide isomerase homolog (PDIp) is an intracellular estrogen-binding protein that modulates estrogen levels and actions in target cells.

  2009cited by this paper
• Alteration of protein glycosylation in liver diseases.

  2009cited by this paper
• Core fucosylation of E‐cadherin enhances cell–cell adhesion in human colon carcinoma WiDr cells

  2009cited by this paper
• Role of Tissue Factor in Cancer

  2009cited by this paper
• Identification of Proteomic Differences between Squamous Cell Carcinoma of the Lung and Bronchial Epithelium*S

  2009cited by this paper
• Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer

  2009cited by this paper
• Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• 2-DE analysis of breast cancer cell lines 1833 and 4175 with distinct metastatic organ-specific potentials: comparison with parental cell line MDA-MB-231.

  2008cited by this paper
• Towards a comprehensive proteome of normal and malignant human colon tissue by 2‐D‐LC‐ESI‐MS and 2‐DE proteomics and identification of S100A12 as potential cancer biomarker

  2008cited by this paper
• Percutaneous laser treatment of atherosclerosis: An overview of emerging techniques

  2007cited by this paper
• Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.

  2007cited by this paper
• The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D.

  2007cited by this paper
• Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma.

  2007cited by this paper
• Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum.

  2006cited by this paper
• Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation.

  2006cited by this paper
• Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways

  2005cited by this paper
• Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy

  2005cited by this paper
• Overexpressed Decorin in Pancreatic Cancer

  2004cited by this paper
• Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population

  2004cited by this paper
• In vivo selective and distant killing of cancer cells, using adenovirus‐mediated decorin gene transfer

  2003cited by this paper
• Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer

  2003cited by this paper
• Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47.

  2002cited by this paper
• Immunohistochemical detection of the 150‐kDa oxygen‐regulated protein in bladder cancer

  2002cited by this paper
• Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines.

  2001cited by this paper
• Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.

  2001cited by this paper
• In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin.

  1999cited by this paper
• 150-kDa Oxygen-regulated Protein (ORP150) Suppresses Hypoxia-induced Apoptotic Cell Death*

  1999cited by this paper
• Amplification of oncogenes in human cancer cells

  1998cited by this paper
• Expression of the 150-kd oxygen-regulated protein in human breast cancer.

  1998cited by this paper
• Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.

  1997cited by this paper
• The role of cathepsin D in the invasiveness of human breast cancer cells.

  1993cited by this paper

• Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer

  2025cites this paper
• Serum N-glycoproteomics characterization of differential N-glycosylation in schizophrenia.

  2025cites this paper
• Mass spectrometry analysis of intact protein N-glycosylation signatures of cells and sera in pancreatic adenocarcinomas

  2024cites this paper
• Mass spectrometry-based structure-specific N-glycoproteomics and biomedical applications

  2024cites this paper
• Functional prediction of the potential NGLY1 mutations associated with rare disease CDG

  2024cites this paper
• Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm

  2023cites this paper
• Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.

  2023cites this paper
• High-throughput N-glycoproteomics with fast liquid chromatographic separation.

  2023cites this paper
• Strategies for Proteome-Wide Quantification of Glycosylation Macro- and Micro-Heterogeneity

  2022cites this paper
• Aberrant N-glycolylneuraminic acid in breast MCF-7 cancer cells and cancer stem cells

  2022cites this paper
• Targeting Glycans for CAR Therapy: the Advent of Sweet CARs.

  2022cites this paper
• Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.

  2022cites this paper
• Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.

  2022cites this paper
• Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases

  2021cites this paper